医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2015年
30期
31-31
,共1页
重组人促红细胞生成素-α%癌性贫血%疗效%安全性
重組人促紅細胞生成素-α%癌性貧血%療效%安全性
중조인촉홍세포생성소-α%암성빈혈%료효%안전성
Recombinant human erythropoietin alpha%Anemia of cancer%Ef icacy%Safety
目的观察重组人促红细胞生成素-α(rhEPO)治疗癌性贫血的最佳时间、疗效以及安全性。方法临床纳入我院70例经病理学检查确诊为癌症并伴有非髓性贫血患者，化疗前患者血红蛋白(Hb)水平100~120g/L。根据患者rhEPO使用时间的不同分为早使用组与晚使用组。早使用组在化疗的同时即给予rhEPO皮下注射，晚实验组在Hb<90g/L时给予rhEPO皮下注射。对于治疗期间出现铁缺乏、疗效不明显的患者加用琥珀酸亚铁0.1g口服，3次/d。观察两组患者治疗前后Hb以及血细胞比容(HCT)水平，对比两组患者治疗前期不良反应发生情况。结果治疗0~4w、5~8w、9~12w，早使用组Hb水平为(116.8±6.7)g/L、(120.3±8.2)g/L、(128.1±10.3)g/L，HCT水平分别为(0.37±0.09)、(0.39±0.06)、(0.41±0.04)；晚使用组Hb水平为(108.6±5.9)g/L、(107.3±9.9)g/L、(105.0±8.7)g/L，HCT水平分别为(0.31±0.03)、(0.29±0.05)、(0.27±0.01)，组间差异均有显著性(<0.05)。两组患者治疗期间均未发生严重不良反应，主要不良反应为低热、皮疹、乏力以及食欲下降等。结论化疗同时即给予rhEPO注射，能够有效提高患者Hb以及Hct水平，改善患者贫血，且药物不良反应较低。
目的觀察重組人促紅細胞生成素-α(rhEPO)治療癌性貧血的最佳時間、療效以及安全性。方法臨床納入我院70例經病理學檢查確診為癌癥併伴有非髓性貧血患者，化療前患者血紅蛋白(Hb)水平100~120g/L。根據患者rhEPO使用時間的不同分為早使用組與晚使用組。早使用組在化療的同時即給予rhEPO皮下註射，晚實驗組在Hb<90g/L時給予rhEPO皮下註射。對于治療期間齣現鐵缺乏、療效不明顯的患者加用琥珀痠亞鐵0.1g口服，3次/d。觀察兩組患者治療前後Hb以及血細胞比容(HCT)水平，對比兩組患者治療前期不良反應髮生情況。結果治療0~4w、5~8w、9~12w，早使用組Hb水平為(116.8±6.7)g/L、(120.3±8.2)g/L、(128.1±10.3)g/L，HCT水平分彆為(0.37±0.09)、(0.39±0.06)、(0.41±0.04)；晚使用組Hb水平為(108.6±5.9)g/L、(107.3±9.9)g/L、(105.0±8.7)g/L，HCT水平分彆為(0.31±0.03)、(0.29±0.05)、(0.27±0.01)，組間差異均有顯著性(<0.05)。兩組患者治療期間均未髮生嚴重不良反應，主要不良反應為低熱、皮疹、乏力以及食欲下降等。結論化療同時即給予rhEPO註射，能夠有效提高患者Hb以及Hct水平，改善患者貧血，且藥物不良反應較低。
목적관찰중조인촉홍세포생성소-α(rhEPO)치료암성빈혈적최가시간、료효이급안전성。방법림상납입아원70례경병이학검사학진위암증병반유비수성빈혈환자，화료전환자혈홍단백(Hb)수평100~120g/L。근거환자rhEPO사용시간적불동분위조사용조여만사용조。조사용조재화료적동시즉급여rhEPO피하주사，만실험조재Hb<90g/L시급여rhEPO피하주사。대우치료기간출현철결핍、료효불명현적환자가용호박산아철0.1g구복，3차/d。관찰량조환자치료전후Hb이급혈세포비용(HCT)수평，대비량조환자치료전기불량반응발생정황。결과치료0~4w、5~8w、9~12w，조사용조Hb수평위(116.8±6.7)g/L、(120.3±8.2)g/L、(128.1±10.3)g/L，HCT수평분별위(0.37±0.09)、(0.39±0.06)、(0.41±0.04)；만사용조Hb수평위(108.6±5.9)g/L、(107.3±9.9)g/L、(105.0±8.7)g/L，HCT수평분별위(0.31±0.03)、(0.29±0.05)、(0.27±0.01)，조간차이균유현저성(<0.05)。량조환자치료기간균미발생엄중불량반응，주요불량반응위저열、피진、핍력이급식욕하강등。결론화료동시즉급여rhEPO주사，능구유효제고환자Hb이급Hct수평，개선환자빈혈，차약물불량반응교저。
Objective To observe the best time and ef icacy and safety ef ects of recombinant human erythropoietin alpha (rhEPO)for the treatment of anemia of cancer.Methods 70 cases of patients, pathological y diagnosed as cancer accompanied by non myeloid anemia,were selected in our hospital.Hemoglobin (Hb)level of Pre chemotherapy patients were 100~120g/L.According to the dif erent rhEPO patients using time,they were divided into the early and late use group.Early use of group at the time of chemotherapy is given by subcutaneous injection of rhEPO,late in the experiment group Hb<90g/L when it was given by subcutaneous injection of rhEPO.For treatment during iron deficiency,the ef ect was not obvious in patients with 0.1g by fer ous succinate oral y,3 times a day.Two groups were observed before and after treatment in patients with Hb and the hematocrit(HCT)levels,compared two groups of patients with the treatment of early stage the occur ence of adverse reactions. Results The treatment of 0~4 weeks,5~8 weeks,9~12 weeks,Hb level of early use of group were(116.8±6.7)g/L,(120.3±8.2)g/L,(128.1±10.3)g/L,HCT levels were(0.37±0.09)and(0.39±0.06)and(0.41±0.04);Hb level of late use groups were (108.6±5.9)g/L,(107.3±9.9)g/L,(105±8.7)g/L,HCT levels were (0.31±0.03)and (0.29±0.05)and (0.27±0.01),the dif erence between groups was significant ( <0.05). During the period of treatment,the patients of two groups were no serious adverse reactions,the main adverse reactions were fever,rash,fatigue and decreased appetite,etc.Conclusion Chemotherapy given rhEPO injection can ef ectively improve the patients with Hb and Hct level of patients with anemia,improve,and drug adverse reaction is lower.
